Irinotecan Fresenius Kabi

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Fresenius Kabi, is a topoisomerase I inhibitor presented as a sterile powder for intravenous use. It is employed in the treatment of colorectal cancer and metastatic colorectal cancer in adult patients.

GNH USA supplies Irinotecan Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan is an antineoplastic agent used in colorectal cancer treatment pathways.

Colorectal cancer: improves survival when used in combination chemotherapy regimens. Metastatic colorectal cancer: reduces tumor burden and extends progression‑free survival. Adjuvant therapy for stage III colorectal cancer: administered after surgical resection to lower recurrence risk.

Irinotecan may cause a range of adverse reactions.

Common Side Effects: - Nausea and vomiting - Diarrhea, often severe - Neutropenia and other blood count reductions - Alopecia (hair loss) - Fatigue and weakness - Mild liver enzyme elevations

Serious or Rare Side Effects: - Febrile neutropenia - Severe colitis or intestinal perforation - Hepatic toxicity with jaundice - Anaphylactic or severe allergic reactions - Tumor lysis syndrome - Life‑threatening electrolyte disturbances

Before initiating therapy, clinicians should evaluate patient‑specific risk factors. - Renal function: assess creatinine clearance and adjust if necessary. - Hepatic function: monitor liver enzymes and bilirubin levels. - Myelosuppression: perform baseline and periodic complete blood counts. - Diarrhea: initiate prophylactic loperamide and educate patients on early reporting. - Pregnancy: avoid use; potential fetal risk is unknown. - Store at controlled room temperature: keep in original container, protect from light and moisture.

Irinotecan can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin) may markedly reduce exposure. - UGT1A1 inhibitors (e.g., atazanavir) can increase SN‑38 levels and toxicity. - Concurrent myelosuppressive agents may cause profound bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Anticoagulants: heightened bleeding risk due to mucosal injury. - Drugs causing electrolyte imbalance (e.g., diuretics) may exacerbate diarrhea‑related losses. - Radiation therapy to the abdomen: additive gastrointestinal toxicity.